While urolithin A may be able to promote better mitochondrial health by supporting mitophagy,7 there currently isnt any research to suggest that the compound could benefit primary or genetic mitochondrial diseases (e.g., Leigh syndrome, Kearns-Sayre syndrome, Leber hereditary optic neuropathy, etc.).16 Some experts suggest that it could be worth investigating whether mitophagy activation could act as a novel strategy to treat these diseases, but that research hasnt been conducted yet.17 18 19 When that happens, well update this information
More clinical evidence is needed before BPC-157 can be formally recognized as a treatment for specific medical conditions
Th17 cells in primary Sjogren's syndrome negatively correlate with increased Roseburia and Coprococcus
This dual anti-inflammatory and antimicrobial profile makes KPV distinct among all peptides for gut health research currently documented in peer-reviewed literature
Maintenance then reduces to 2mg once every 7-14 days
These are ranges seen across research-supply listings in 2026, not a quote from any single vendor
